WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:
H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference: Fireside Chat on October 8, 2024 at 1:30 pm ET
About Arbutus
Contact Information
Investors and Media
